Cutaneous malignant melanoma after immunosuppressive therapy.
Malignant neoplasm after immunosuppressive therapy is a well-known entity. Though a considerable number of such lesions are cutaneous in origin, melanoma has rarely been reported. In this communication, six such melanoma cases are reported.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D002648:Child; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D008223:Lymphoma / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000209:etiology* / Q000601:surgery; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000532:radiotherapy; D011565:Psoriasis / Q000188:drug therapy; D012878:Skin Neoplasms / Q000209:etiology* / Q000601:surgery
D000970:Antineoplastic Agents